Clinical Research Pharma Companies Therapies 
H1 Blog
MAY 4, 2023
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.
The Pharma Data
OCTOBER 16, 2020
As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 17, 2020
Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. TISSIUM – France’s TISSIUM announced Michel Thérin has been appointed to the company ’ s board of directors. Thérin is the president of Advanced Therapies at Siemens Healthineers. based Rinri Therapeutics.
Vial
DECEMBER 8, 2023
With technological innovation and scientific research propelling the development of new therapies, anticipation for the future is high. The goal of this therapy is to replace a disease-causing gene with a healthy one, disable a disease-causing gene, or introduce a new gene to aid in fighting a disease.
The Pharma Data
OCTOBER 14, 2020
Food and Drug Administration granted Breakthrough Therapy designation to France-based Inventiva’s experimental NASH treatment lanifibranor. Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. Axol Bioscience – Based in the U.K.,
Vial
MARCH 1, 2024
Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. billion by 2029.
The Anticancer Fund
JUNE 7, 2022
However, patients treated with subsequent therapies, including rechallenge with previous treatments some showed very encouraging responses - intriguingly suggesting the combination treatment may work to reverse drug resistance in this population with few other options. You can easily subscribe to this newsletter by clicking here.
Expert insights. Personalized for you.
52 
Let's personalize your content